FDA Grants Priority Review to AstraZeneca and Daiichi Sankyo’s Enhertu for First-Line HER2-Positive…
AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental Biologics License Application (sBLA) for Enhertu…
Read More...
Read More...
